Published in J Clin Oncol on January 04, 2010
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy | NCT00793975
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PLoS One (2014) 1.80
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest (2010) 1.53
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 1.26
Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med (2014) 1.24
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res (2013) 1.16
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A (2013) 1.09
Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer (2013) 1.08
Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets (2010) 1.07
Vascular endothelial growth factor a inhibition in gastric cancer. Gastric Cancer (2014) 1.07
Have we overestimated the benefit of human(ized) antibodies? MAbs (2010) 1.05
Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther (2012) 1.05
Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol (2012) 1.05
Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res (2010) 1.01
Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol (2012) 1.01
Immunotherapy targets in pediatric cancer. Front Oncol (2012) 0.97
Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther (2013) 0.96
Metastatic gastric cancer - focus on targeted therapies. Biologics (2012) 0.96
Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist (2011) 0.96
Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist (2013) 0.94
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res (2015) 0.94
Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol (2014) 0.92
Drugs derived from phage display: from candidate identification to clinical practice. MAbs (2014) 0.91
Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol (2012) 0.91
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol (2016) 0.91
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol (2014) 0.90
Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci (2014) 0.89
Targeting angiogenesis in metastatic breast cancer. Oncologist (2012) 0.89
The progress of targeted therapy in advanced gastric cancer. Biomark Res (2013) 0.89
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther (2011) 0.87
Characteristics of human Ewing/PNET sarcoma models. Ann Saudi Med (2011) 0.87
Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) (2013) 0.87
Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol (2013) 0.87
Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist (2011) 0.87
Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell (2011) 0.87
Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol (2015) 0.86
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol (2014) 0.86
Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biol Ther (2011) 0.86
Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol (2016) 0.86
Antibody phage display libraries: contributions to oncology. Int J Mol Sci (2012) 0.85
Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget (2010) 0.84
Molecular targeting to treat gastric cancer. World J Gastroenterol (2014) 0.84
Targeting angiogenesis in squamous non-small cell lung cancer. Drugs (2014) 0.83
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer (2016) 0.82
Ramucirumab: preclinical research and clinical development. Onco Targets Ther (2014) 0.81
Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121. Mol Pharm (2012) 0.81
Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Invest New Drugs (2011) 0.81
Immunotherapy of brain cancers: the past, the present, and future directions. Clin Dev Immunol (2011) 0.81
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol (2016) 0.81
Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer. Onco Targets Ther (2016) 0.80
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. Onco Targets Ther (2017) 0.79
VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. Oncotarget (2016) 0.79
The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. Oncologist (2013) 0.79
Phage display-derived human antibodies in clinical development and therapy. MAbs (2016) 0.79
Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res (2014) 0.79
Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol (2011) 0.79
Clinical utility of ramucirumab in advanced gastric cancer. Biologics (2015) 0.79
Targeting angiogenesis in melanoma: prospects for the future. Ther Adv Med Oncol (2010) 0.79
Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol (2015) 0.79
Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake? Transl Lung Cancer Res (2016) 0.78
Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian J Med Paediatr Oncol (2014) 0.78
Gastric Cancer: New Drugs - New Strategies. Gastrointest Tumors (2015) 0.78
Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat (2011) 0.78
The current state of targeted agents in rectal cancer. Int J Surg Oncol (2012) 0.78
An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis (2013) 0.78
Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov (2016) 0.78
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Eur J Cancer (2015) 0.76
Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers. Ther Clin Risk Manag (2015) 0.76
Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer Gene Ther (2012) 0.76
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer (2015) 0.76
Targeting lymphatic vessel functions through tyrosine kinases. J Angiogenes Res (2010) 0.76
Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol (2015) 0.76
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol (2016) 0.76
Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC. Medicine (Baltimore) (2016) 0.75
Update on Anti-Angiogenesis Therapy in Colorectal Cancer. Curr Colorectal Cancer Rep (2015) 0.75
The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. Oncoimmunology (2016) 0.75
Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget (2016) 0.75
Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. Therap Adv Gastroenterol (2015) 0.75
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. Oncologist (2016) 0.75
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res (2016) 0.75
Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. Cancer Chemother Pharmacol (2016) 0.75
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma. Onco Targets Ther (2016) 0.75
Ramucirumab (Cyramza): A Breakthrough Treatment for Gastric Cancer. P T (2015) 0.75
Targeted therapy in gastric cancer. Eur Surg (2016) 0.75
Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol (2011) 0.75
Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis. Oncotarget (2016) 0.75
Biologics in combination with chemotherapy for gastric cancer: is this the answer? Expert Opin Pharmacother (2015) 0.75
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther (2016) 0.75
Drug monographs: ibrutinib and ramucirumab. Hosp Pharm (2014) 0.75
Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs (2015) 0.75
Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. Int J Clin Oncol (2016) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) (1999) 4.85
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res (1999) 4.20
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 4.00
Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene (1990) 3.66
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res (2005) 2.76
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev (1998) 2.55
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer (2005) 2.49
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol (2005) 2.23
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol (2006) 1.81
Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev (1996) 1.75
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther (2007) 1.64
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer (2000) 1.58
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs (2007) 1.37
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem (2003) 1.33
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res (2007) 1.32
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol (2007) 1.25
E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer (2003) 1.21
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res (2003) 1.09
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer (2002) 1.09
Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol (2008) 1.08
Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets (2002) 0.98
Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs (1999) 0.88
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol (2004) 5.08
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol (2002) 3.53
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol (2009) 3.42
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Clinical applications of metabolomics in oncology: a review. Clin Cancer Res (2009) 2.91
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res (2004) 2.79
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol (2008) 2.65
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer (2012) 2.59
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol (2008) 2.57
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol (2006) 2.48
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol (2009) 2.40
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood (2013) 2.39
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol (2009) 2.36
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int (2011) 2.20
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol (2004) 2.13
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.96
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.95
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res (2007) 1.89
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res (2007) 1.87
The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer (2010) 1.84
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol (2002) 1.84
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2006) 1.84
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res (2007) 1.80
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol (2003) 1.80
Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol (2009) 1.79
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res (2006) 1.75
Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer (2003) 1.75
Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro. Blood (2002) 1.72
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72